18The Wider World: Other Manufacturers and the Pioneers' Electrodes

FThree makers — and the rest

For most of this chapter, “the manufacturers” has meant three companies whose arrays you will meet in almost every operating theatre. That concentration is real, but it is not the whole picture. A handful of other companies build cochlear implants today, and behind all of them stand the original pioneer devices whose electrodes proved the idea could work at all. Knowing this wider landscape matters for two practical reasons: you will occasionally meet a patient carrying a legacy or non-mainstream device, and the newer low-cost makers are reshaping who in the world can be implanted at all.

TThe pioneers' electrodes

The first implant to reach patients in numbers carried a single electrode. William House and Jack Urban's House/3M device, the first cochlear implant approved by the US FDA in 1984, placed one active contact in the scala tympani and delivered an analog signal. It could not convey place-of-frequency information, but it restored sound awareness and aided lip-reading for over a thousand recipients — and it settled the safety question that opened the field.[1973]

The other landmark pioneer electrode took the opposite design choice. The University of Utah's Ineraid (marketed by Symbion) used six electrodes on a straight carrier connected through a percutaneous plug — a connector passing through the skin behind the ear, with no internal electronics. Direct wired access to each electrode made it the great research workhorse of the 1980s: investigators could drive the array with any stimulus they wished, and much of what we learned about multichannel speech coding came from Ineraid recipients. Its very strength — a hole through the skin — was also why transcutaneous, fully implanted designs ultimately won the market, and the Ineraid was never FDA-approved.[2015]

TOticon Medical / Neurelec

The longest-running “fourth manufacturer” traces to France. The Chouard lineage became Neurelec, later Oticon Medical, whose Digisonic SP and Neuro Zti implants carried a 20-electrode lateral-wall array driven by a system with its own distinctive features — including a notably thin, robust titanium implant body. Multicentre studies reported outcomes broadly comparable to the established makers.[2019] In a significant consolidation of the field, Oticon Medical's parent company divested the cochlear-implant business to Cochlear, with the transaction completing in 2024 — so while many patients still wear and rely on these devices, the product line is now being wound into a larger maker rather than developed independently. It is exactly the kind of legacy device a clinic must still be able to recognise and support for decades.

TChina and Korea's makers

The most dynamic recent growth is in Asia, where domestic manufacturers build arrays explicitly to lower cost and widen access. China's Nurotron Venus system uses a 24-electrode lateral-wall array, developed with experienced array engineers and tested against international mechanical and reliability standards.[2018] Shanghai-based LISTENT, founded on technology from Fudan University, markets the LCI-20PI, a 20-electrode lateral-wall implant evaluated in multicentre Chinese trials.[2025] In South Korea, the start-up TODOC took a different route to value, laser-patterning a 32-channel array — more physical contacts than any mainstream commercial device — for its SULLIVAN system, aiming to undercut the established makers on price.[2021]

CMore contacts, lower cost

It is tempting to rank these devices by electrode count, but the count is misleading. As an earlier module showed, recipients use only about four to eight truly independentchannels regardless of how many physical contacts an array carries, because injected current spreads through the perilymph and excites neighbouring neurons. TODOC's 32 contacts therefore do not buy four times the resolution of an 8-channel map; the channel ceiling is biological, not a contact-count limit.[1991] What the newer makers genuinely change is price. A device that performs comparably at a fraction of the cost is not a minor engineering footnote — for a health system that could previously afford to implant only a handful of children, it can be the difference between a programme and no programme at all.

CWhy it matters at the clinic

Two clinical messages follow. First, legacy and non-mainstream devices walk into clinics: a teenager with a childhood Neurelec implant, a research participant who still wears an Ineraid, an adult implanted abroad with a Nurotron processor. You should be able to recognise the maker, know that programming and spare parts may need that specific company's support, and counsel realistically about upgrade paths — especially where a product line has been discontinued or absorbed. Second, the rise of affordable arraysis central to global and Indian access: most of the world's deaf children live where the mainstream device price is prohibitive, and lower-cost makers — together with refurbishment programmes and local manufacturing ambitions — are how the field hopes to close that gap. A comprehensive view of “the devices” therefore has to include not just the best-performing array but the one a given patient can actually receive.[2013]